ASP 5878

Drug Profile

ASP 5878

Alternative Names: ASP5878

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Oct 2015 Phase-I development for Solid tumours is ongoing in Japan (NCT02038673)
  • 01 Nov 2013 Phase-I clinical trials in Solid tumours in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top